Companies
Olon
a biopharmaceutical CDMO that in October 2025 announced a partnership with Ajinomoto Bio-Pharma Services, strengthening European cGMP fermentation and API capacity for steroid and other complex APIs.
- Country
- Italy
Commercial
Steroid API / CDMO
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | €25 million non-convertible notes issued via US private placement, with an associated US$200 million shelf facility | whitecase.com |
| Capacity | Total fermentation capacity of 5,000 m3 | olonspa.com · pharmasource.global |
| Certification | ISO 14001, ISO 45001, cGMP, and GFSI (FSSC 22000) compliant; production sites in Capua, Garessio, Settimo Torinese, Mahad, and Derivados Químicos are ISO 14001 certified | olonspa.com |
| Regulatory approval | Olon API India Pvt. Ltd. (Mahad site) confirmed operating at an acceptable level of compliance with WHO GMP Guidelines for APIs as of September 2025 | extranet.who.int |
| Production site | 14 manufacturing sites worldwide (9 in Italy, 2 in France, 1 in Spain, 1 in the United States, 1 in India) | olonspa.com |
| Headcount | Over 2,800 employees | extranet.who.int · olonspa.com |
| Revenue | €615 million for the full year 2024 | olonspa.com |
Independent sources: extranet.who.int · pharmasource.global · whitecase.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic steroids (fermentation & biocatalytic API) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.